To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.

Inclusion Criteria:

• Healthy adult volunteers aged over 19 years
• Subjects who have over 50kg and BMI more than 18.5kg/m^2 and less than 29.9kg/m^2
• Subjects who are eligible for this study as determined by clinical laboratory test results, urine test results, vital sign measurements, 12-lead ECG results, and physical examination findings during screening.
• Subjects must agree to practice a medically acceptable method of birth control and should not donate sperm or eggs until 28 days after last dose of study drug.
• Subjects who provided written informed consent to participate in this study and voluntarily taken part in during the entire study period

Exclusion Criteria:

• • Subject with any clinically significant cardiovascular, respiratory, endocrinology, infectious disease, ophthalmology, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease

  • History of gastrointestinal disease (except for appendectomy or herniotomy) or surgery (ex. Crohn's disease, ulcer) that may affect the absorption of a given drug
  • Medical history or evidence that can affect absorption, distribution, metabolism and excretion of a given drug
  • Subject with symptoms of acute disease within 28days prior to study medication dosing
  • Drugs or other drugs (aspirin, antibiotics, etc.) that contain the following drug categories or components of the same strain have an overactive or clinically significant history of hypersensitivity:
  • Subject with a history of drug abuse or urinalysis positive
  • Subject with clinically significant active chronic disease
  • Subject with genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.
  • Genetic myopathic disorder or related family history
  • Positive test results for HBs Ab, HCV Ab, Anti HIV(AIDS), RPR Ab
  • Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)
  • Subject who cannot take standard meal in hospitalization
  • Present history of hypothyroidism or clinically significant assay
  • Subjects who donated whole blood or partial blood within 2 or 1 month, respectively, prior to the first administration.
  • Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 30days prior to study medication dosing
  • Smokers whose average daily smoking amount exceeds 10 cigarettes per day within 3 months before the first dosing day and those who can't quit from 48 hours before dosing to the time of the last blood sampling.
  • Subjects who judged ineligible by the investigator